UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups

Arthritis & rheumatology (Hoboken, N.J.), 2023-08, Vol.75 (8), p.1325-1327

2023

Volltextzugriff (PDF)

Estimating the burden of total knee replacement in the United States

Journal of bone and joint surgery. American volume, 2013-03, Vol.95 (5), p.385

2013

Volltextzugriff (PDF)

Drug Evaluation during the Covid-19 Pandemic

The New England journal of medicine, 2020-06, Vol.382 (24), p.2282-2284

2020

Volltextzugriff (PDF)

Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021

JAMA internal medicine, 2023-03, Vol.183 (3), p.275

2023

Volltextzugriff (PDF)

Estimated Medicare Part B Savings From Inflationary Rebates

JAMA : the journal of the American Medical Association, 2023-01, Vol.329 (1), p.89

2023

Volltextzugriff (PDF)

Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings

JAMA internal medicine, 2023-01, Vol.183 (1), p.82

2023

Volltextzugriff (PDF)

Direct-to-Consumer Drug Company Pharmacies

JAMA : the journal of the American Medical Association, 2024-03, Vol.331 (12), p.1003

Rome, Benjamin N

2024

Volltextzugriff (PDF)

Placing a price on medical device innovation: the example of total knee arthroplasty

PloS one, 2013-05, Vol.8 (5), p.e62709-e62709

2013

Volltextzugriff (PDF)

State Coverage and Reimbursement of Antiobesity Medications in Medicaid

JAMA : the journal of the American Medical Association, 2024-04, Vol.331 (14), p.1230

2024

Volltextzugriff (PDF)

Addressing High Drug Prices by Reforming Pharmacy Benefit Managers

The Journal of law, medicine & ethics, 2023-01, Vol.51 (S2), p.46-51

Rome, Benjamin N

2023

Volltextzugriff (PDF)

The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic

Journal of bone and joint surgery. American volume, 2012-02, Vol.94 (3), p.201

2012

Volltextzugriff (PDF)

Spending on Targeted Therapies for Duchenne Muscular Dystrophy

JAMA : the journal of the American Medical Association, 2024-04, Vol.331 (13), p.1151

2024

Volltextzugriff (PDF)

Reforming Pharmacy Benefit Managers — A Review of Bipartisan Legislation

The New England journal of medicine, 2023-11, Vol.389 (18), p.1640-1643

2023

Volltextzugriff (PDF)

Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare

JAMA : the journal of the American Medical Association, 2023-04, Vol.329 (15), p.1283

2023

Volltextzugriff (PDF)

A Comparison of Patient-Reported and Measured Range of Motion in a Cohort of Total Knee Arthroplasty Patients

The Journal of arthroplasty, 2014-07, Vol.29 (7), p.1378-1382.e1

2014

Volltextzugriff (PDF)

Patient Out‐of‐Pocket Costs Following the Availability of Biosimilar Versions of Infliximab

Clinical pharmacology and therapeutics, 2023-01, Vol.113 (1), p.90-97

2023

Volltextzugriff (PDF)

Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?

JAMA internal medicine, 2021-08, Vol.181 (8), p.1034

2021

Volltextzugriff (PDF)

Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study

The American heart journal, 2021-03, Vol.233, p.109-121

2021

Volltextzugriff (PDF)

The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs

Chest, 2022-08, Vol.162 (2), p.433-435

2022

Volltextzugriff (PDF)

Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis

Clinical infectious diseases, 2020-10, Vol.71 (7), p.1671-1675

2020

Volltextzugriff (PDF)

Raising Medicaid Rebates For Drugs With Accelerated Approval

Health affairs (Millwood, Va.), 2021-12, Vol.40 (12), p.1935-6

2021

Volltextzugriff (PDF)

Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis

JAMA neurology, 2024-01, Vol.81 (1), p.85

2024

Volltextzugriff (PDF)

Will Medicare Price Negotiation Delay Cancer-Drug Launches?

The New England journal of medicine, 2023-10, Vol.389 (17), p.1543-1545

2023

Volltextzugriff (PDF)

Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States

JAMA internal medicine, 2021-07, Vol.181 (7), p.995

2021

Volltextzugriff (PDF)

Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20

Health affairs (Millwood, Va.), 2023-06, Vol.42 (6), p.770-9A

2023

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(93)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Biosimilar Competition for Humira Is Here: Signs of Hope Despite Early Hiccups

Estimating the burden of total knee replacement in the United States

Drug Evaluation during the Covid-19 Pandemic

Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021

Estimated Medicare Part B Savings From Inflationary Rebates

Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings

Direct-to-Consumer Drug Company Pharmacies

Placing a price on medical device innovation: the example of total knee arthroplasty

State Coverage and Reimbursement of Antiobesity Medications in Medicaid

Addressing High Drug Prices by Reforming Pharmacy Benefit Managers

The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic

Spending on Targeted Therapies for Duchenne Muscular Dystrophy

Reforming Pharmacy Benefit Managers — A Review of Bipartisan Legislation

Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare

A Comparison of Patient-Reported and Measured Range of Motion in a Cohort of Total Knee Arthroplasty Patients

Patient Out‐of‐Pocket Costs Following the Availability of Biosimilar Versions of Infliximab

Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?

Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study

The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs

Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis

Raising Medicaid Rebates For Drugs With Accelerated Approval

Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis

Will Medicare Price Negotiation Delay Cancer-Drug Launches?

Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States

Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20

Suchergebnisse filtern